Ocular side effects of the taxane-based chemotherapy – do only vascular disorders matter? Review article

Article Sidebar

PDF


Published: Sep 30, 2019
DOI: https://doi.org/10.24292/01.OR.319200619
Keywords:
taxanes, chemotherapy, ophthalmological complications

Main Article Content

Anna Rzeszotarska
Department of Ophthalmology, Poznań University of Medical Sciences, Poland
Agata Stodolska-Nowak
Department of Ophthalmology, Poznań University of Medical Sciences, Poland
Joanna Kufel-Grabowska
Surgical, Oncological and Endoscopic Gynaecology Department, Greater Poland Cancer Centre, Poznań, Poland
Błażej Nowakowski
Surgical, Oncological and Endoscopic Gynaecology Department, Greater Poland Cancer Centre, Poznań, Poland
Jarosław Kocięcki
Department of Ophthalmology, Poznań University of Medical Sciences, Poland

Abstract

Taxanes, whose mechanism of action is based on blocking the cells’ division of cells, have been commonly used in the chemotherapy process for over two decades. The indications for the use of taxanes include ovarian cancer, breast cancer, lung cancer, prostate cancer, some of gastrointestinal malignant tumors or Kaposi sarcoma. Currently, chemotherapy based on taxanes, as well as every cytostatic medicine, allows to improve survival outcomes in many patients with diagnosed malignancies, although it also involves the occurrence of adverse effects. These adverse events may be life-threatening or at least they can decline the patient’s quality of life. The main aim of this paper is to feature possible ocular side effects during taxane based chemotherapy. Physicians taking care of patients during chemotherapy based on taxanes, as well as on every other cytostatic medicine, should be aware of these probable ocular complications. An early diagnosis of ophthalmic complications caused by chemotherapy makes it possible to avoid long-lasting adverse effects.

Downloads

Download data is not yet available.

Metrics

Metrics Loading ...

Article Details

How to Cite
1.
Rzeszotarska A, Stodolska-Nowak A, Kufel-Grabowska J, Nowakowski B, Kocięcki J. Ocular side effects of the taxane-based chemotherapy – do only vascular disorders matter?. OncoReview [Internet]. 2019Sep.30 [cited 2024Nov.22];9(3(35):59-3. Available from: https://journalsmededu.pl/index.php/OncoReview/article/view/1088
Issue
Vol 9 No 3(35) (2019)
Section
CARDIO-ONCOLOGY
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.

Copyright: © Medical Education sp. z o.o. This is an Open Access article distributed under the terms of the Attribution-NonCommercial 4.0 International (CC BY-NC 4.0). License (https://creativecommons.org/licenses/by-nc/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.

Address reprint requests to: Medical Education, Marcin Kuźma (marcin.kuzma@mededu.pl)

References

1. Mutschler E, Geisslinger G, Kroemer HK. Farmakologia i toksykologia. Wyd. IV. (ed. pol. Droździk M). MedPharm Polska, Wrocław 2016: 882-884.
2. Eisenhauer EA, Vermorken JB. The taxoids. Comparative clinical pharmacology and therapeutic potential. Drugs 1998; 55: 5-30.
3. Abal M, Andreu JM, Barasoain I. Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets 2003; 3: 193-203.
4. Wani MC, Taylor HL, Wall ME et al. Plant antitumour agents. VI: The isolation and structure of taxol: a novel antileukemic and antitumour agents from Taxus brevifolia. J Am Chem Soc 1971; 93: 2325-7.
5. Schiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by taxol. Nature 1979; 277: 665-7.
6. Charakterystyka Produktu Leczniczego – paklitaksel.
7. Fumoleau P, Seidman AD, Trudeau ME et al. Docetaxel: a new active agent in the therapy of metastatic breast cancer. Expert Opin Investig Drugs 1997; 6: 1853-65.
8. Charakterystyka Produktu Leczniczego – docetaksel.
9. Charakterystyka Produktu Leczniczego – abraxane.
10. de Bono JS, Oudard S, Ozguroglu M et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 2010; 376: 1147-54.
11. Guastalla III JP, Diéras V. The taxanes: toxicity and quality of life considerations in advanced ovarian cancer. Br J Cancer 2003; 89: S16-S22.
12. Pazdur R, Kudelka AP, Kavanagh JJ et al. The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev 1993; 19: 351-86.
13. Peroukides S, Alexopoulos A, Kalofonos et al. Cardiovascular effects of treatment with taxanes. J Cardiovasc Med (Hagerstown) 2012; 13(5): 319-24.
14. Capri G, Munzone E, Tarenzi E et al. Optic nerve disturbances: a new form of paclitaxel neurotoxicity. J Natl Cancer Inst 1994; 86: 1099-101.
15. Hofstra LS, de Vries EG, Willemse PH. Ophthalmic toxicity following paclitaxel infusion. Ann Oncol 1997; 8: 1053.
16. Scaioli V, Caraceni A, Martini C et al. Electrophysiological evaluation of visual pathways in paclitaxel-treated patients. J Neurooncol 2006; 77: 79-87.
17. Moloney TP, Xu W, Rallah-Baker K et al. Toxic optic neuropathy in the setting of docetaxel chemotherapy: a case report. BMC Ophthalmol 2014; 14: 18.
18. Noguchi Y, Kawashima Y, Kawara H et al. An Undeniable Case of Optic Neuropathy Due to Cabazitaxel. Gan To Kagaku Ryoho 2016; 43: 777-9.
19. Rowinsky EK, Chaudhry V, Cornblath DR et al. Neurotoxicity of Taxol. J Natl Cancer Inst Monogr 1993; 15: 107-15.
20. Gass JD, Norton EW. Follow-up study of cystoid macular edema following cataract extraction.Trans Am Acad Ophthalmol Otolaryngol 1969; 73: 665-82.
21. Gass JDM. Nicotinic acid maculopathy. Am J Ophth 1973; 76: 500-10.
22. Yokoe T, Fukada I, Kobayashi K et al. Cystoid Macular Edema during Treatment with Paclitaxel and Bevacizumab in a Patient with Metastatic Breast Cancer: A Case Report and Literature Review. Case Rep Oncol 2017; 10: 605-12.
23. Nakao S, Ikeda Y, Emi Y et al. Possibility of Müller Cell Dysfunction as the Pathogenesis of Paclitaxel Maculopathy. Ophthalmic Surg Lasers Imaging Retina 2016; 47: 81-4.
24. Daruich A, Matet A, Moulin A et al. Mechanisms of macular edema: Beyond the surface. Prog Retin Eye Res 2018; 63: 20-68.
25. Kuznetcova TI, Cech P, Herbort CP. The mystery of angiographically silent macular oedema due to taxanes. Int Ophthalmol 2012; 32: 299-304.
26. 26. Telander DG, Sarraf D. Cystoid macular edema with docetaxel chemotherapy and the fluid retention syndrome. Semin Ophthalmol 2007; 22(3): 151-3.
27. Chelala E, Arej N, Antoun J et al. Central Macular Thickness Monitoring after a Taxane-Based Therapy in Visually Asymptomatic Patients. Chemotherapy 2017; 62: 199-204.
28. Amigo MH, Falabella P, Bettarello A et al. Irreversible visual loss after use of paclitaxel. Rev Bras Oftalmol 2015; 74; 254-6.
29. Esmaeli B, Hidaji L, Adinin RB et al. Blockage of the lacrimal drainage apparatus as a side effect of docetaxel therapy. Cancer 2003; 98: 504-7.
30. Chan A, Su C, de Boer RH, Gajdatsy A. Prevalence of excessive tearing in women with early breast cancer receiving adjuvant docetaxel-based chemotherapy. J Clin Oncol 2013; 31: 2123-7.
31. Esmaeli B, Ahmadi MA, Rivera E et al. Docetaxel secretion in tears: association with lacrimal drainage obstruction. Arch Ophthalmol 2002; 120: 1180-2.
32. Esmaeli B, Burnstine MA, Ahmadi MA, Prieto VG. Docetaxel secretion in tears: association with lacrimal drainage obstruction. Arch Ophthalmol 2002; 120: 1180-2.
33. Ahmadi MA, Esmaeli B. Surgical treatment of canalicular stenosis in patients receiving docetaxel weekly. Arch Ophthalmol 2001; 119: 1802-4.
34. Esmaeli B. Management of excessive tearing as a side effect of docetaxel. Clin Breast Cancer 2005; 5: 455-7.
35. Cetinkaya A, Hudak D, Kulwin D. Cicatricial entropion following docetaxel (Taxotere) therapy. Ophthalmic Plast Reconstr Surg 2011; 27: e113-16.
36. Duh EJ, Sun JK, Stitt AW. Diabetic retinopathy: current understanding, mechanisms, and treatment strategies JCI Insight 2017; 2(14): e93751.
37. Karia N. Retinal vein occlusion: pathophysiology and treatment options. Clin Ophthalmol 2010; 4: 809-16.